Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial

The high rates of recurrence and progression—reaching 60–80% and 20–40% at 5 years, respectively—are hallmarks of high-risk non-muscle-invasive bladder cancer (NMIBC) [1, 2]. Several clinical trials have found intravesical bacillus Calmette–Guérin (BCG) treatment with maintenance to be the best bladder-sparing treatment for these high-risk NMIBC patients [3‐5]. However, the administration of BCG is not without toxicity, with 63% of patients reporting local side effects and 31% reporting systemic side effects [6]. Additionally, recent severe global shortages in BCG supply have compromised patient outcomes and left clinicians around the globe scrambling to identify effective and reliable alternative therapies [7‐9].

Hyperthermic intravesical chemotherapy (HIVEC) has shown promise as an alternative to BCG [10]. Key mechanistic benefits of HIVEC over standard room temperature intravesical chemotherapy are improved drug delivery and penetration into the bladder, improved chemotherapy efficacy in heated cancer cells and the triggering of local anticancer immune reactions [11]. Different technologies can be used to achieve bladder heating [12]. Here, we present the results of HIVEC-HR, the first randomized clinical trial of recirculating convective HIVEC using mitomycin C (MMC) compared to BCG in patients with high-risk papillary NMIBC.

In total, 50 patients were randomized, of whom 48 received at least one treatment session. Reasons for not receiving treatment included a new urethral stricture that prevented bladder catheterization and hospitalization due to pneumonia prior to the first instillation (Supplementary Fig. 1). Baseline patient characteristics are shown in Table 1. Mean patient age was 73.5 years and 88% were male. Median follow-up was 33.7 months (interquartile interval: 18.6–37.1). There were 11 recurrences (BCG = 7, HIVEC = 4), 7 disease progressions (BCG = 6, HIVEC = 1), and 11 deaths (BCG = 7, HIVEC = 4) during the trial, 2 of which were due to bladder cancer.

In the ITT analysis, the 24-month RFS was 86.5% for HIVEC and 71.8% for BCG (HR 0.41, 95% CI 0.10–1.66; p = 0.215); the corresponding values in the PP analysis were 95.0% and 75.1%, respectively (HR 0.48; 95% CI 0.11–2.03; p = 0.322). Mean TTR with HIVEC was 21.5 months, while with BCG it was 16.1 months (p = 0.315). The ITT 24-month PFS was 95.7% for HIVEC and 71.8% for BCG (HR 0.14, 95% CI 0.02–1.29; p = 0.071), while in the PP analysis it was 100% for HIVEC and 75.1% for BCG (HR 0.16, 95% CI 0.02–1.4; p = 0.102) (Figs. 1 and 2). At 24 months, CSS was 100% in both treatment groups, and the 24-month OS was similar (91.5% for HIVEC vs 81.8% for BCG, p = 0.498). The cystectomy rate was 4% in the HIVEC arm and 20% in the BCG arm. Cox regression analysis showed the ITT hazard ratios for HIVEC vs BCG for the RFS, PFS, and OS endpoints to be 0.47 (95% CI 0.13–1.61), 0.14 (95% CI 0.02–1.19), and 0.75 (95% CI 0.23–2.48), respectively.

A total of 31 patients (64.6%) reported at least one AE and 23 (47.9%) reported at least one study therapy-related AE (Table 2). There were two patients with grade 4 or 5 study therapy-related AEs, both in the BCG arm. One patient developed urosepsis requiring hospital admission and one died as a consequence of Guillain–Barré syndrome, which was deemed to be treatment related (Supplementary Table 2). The overall rate and grade of study therapy-related AEs were similar between the arms, with slightly more grade ≥ 3 complications in the BCG arm. Two HIVEC patients who developed MMC allergy during induction received monthly maintenance BCG for 6 months. Treatment was discontinued due to study therapy-related AEs in four HIVEC patients and seven BCG patients. Regarding grade 1 and 2 study therapy-related AEs, bladder spasms were more frequent in the HIVEC group. Supplementary Table 3 shows the grading, according to CTCAE (Common Terminology Criteria for Adverse Events) version 4, of the AEs in relation to the treatment.

We have presented results from HIVEC-HR, the first randomized clinical trial comparing recirculating conductive HIVEC and BCG in patients with high-risk papillary NMIBC. The results suggest that HIVEC with MMC induction plus maintenance appears at least comparable to BCG in terms of safety and efficacy. HIVEC did not show any evidence of being worse than BCG with respect to any of the clinical efficacy endpoints. From a safety perspective, we found that both treatments had similar AE profiles to those reported elsewhere [6]. The results of our work are particularly relevant in the current health care environment, in which BCG has limited availability and alternative therapies are needed. Indeed, centers in Europe and North American have implemented conductive HIVEC when BCG is not available [13‐15].

While this is the first randomized trial to use the Combat BRS system to administer HIVEC^® treatment with MMC in high-risk NMIBC, other bladder-heating devices have been tested in this population. Arends et al. compared heated MMC using the Synergo SB-TS 101 device with BCG in 190 intermediate- and high-risk NMIBC patients [16] and found that heated MMC was superior to BCG in patients with papillary tumors (24 month RFS: 78% vs 65%). A second randomized trial similarly compared Synergo-heated MMC with BCG in 104 patients with intermediate- and high-risk NMIBC [17]. Patients with CIS had a worse RFS with heated MMC (HR = 2.06), while those with papillary tumors had a better RFS (HR = 0.50). When our trial was designed, CIS was considered an exclusion criterion based on the aforementioned data. However, currently most of the new drugs for NMIBC are being tested in the BCG-unresponsive population, with promising outcomes for immune checkpoint inhibitors in CIS and for intravesical therapies such as nadofaragene firadenovec in both CIS and papillary neoplasms [18, 19]. Recent data from a retrospective analysis using HIVEC for a mixed BCG-unresponsive population are also encouraging with the added benefit of a better safety profile as compared with systemic therapies [20].

While HIVEC-HR has many strengths, it also has weaknesses. First, the results we present were derived from a phase II pilot trial in which RFS was the main objective (a pilot study is a small-scale exploratory study that tries to answer questions such as the pragmatics of recruitment and whether a larger trial is feasible). Despite this being a phase II trial, RFS was set as the primary outcome due to the urgent need for efficacy data for alternative treatments to BCG in the context of the severe BCG shortage, and this is how the trial was approved by the Regulatory Agencies and Ethics Committees. Despite the value of a pilot study, it has its own limitations, particularly a small sample size. Second, five patients in the BCG group had failed an intravesical treatment before this trial whereas only two patients in the HIVEC group had prior intravesical treatment. Because of the pilot design, the number of patients and the number of events are low, so these differences may have had a significant confounding impact on the results. Third, while the results are interestingly good in favor of HIVEC, the duration of response might be the subject of further evaluation with a longer follow-up.

HIVEC-HR did not mandate repeat TURBT and immediate postoperative chemotherapy and, while there was no significant difference between the arms with respect to these two interventions, future trials should specify their requirement.

HIVEC-HR compared HIVEC and BCG in patients with high-risk papillary NMIBC. This pilot trial suggests that HIVEC with MMC provides comparable safety and efficacy to BCG and represents a reasonable alternative that should be considered during BCG shortages. A larger trial will be required to determine whether HIVEC is superior to BCG in this population.